Ligand Pharmaceuticals Incorporated
LGND
|
|
| |
|
| Trading Volume | 3,083 |
|
|
109.17 - 49.57 |
| Market Cap Full | $ 1.8B |
Quarterly +
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Q1 | 3.4% | 2.4% | 10.1% | -28.7% |
| Q2 | - | 12% | -2% | -20.7% |
| Q3 | - | -3% | -16.9% | -39.8% |
| Q4 | - | -17.8% | 20.7% | 24.4% |
Monthly +
| J | F | M | A | M | J | J | A | S | O | N | D |
| 2025 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.4 | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | |||||||||||
| 2.4 | 8.6 | -7.9 | -0.8 | 17.4 | -3.4 | 32.7 | -3 | - | - | - | -11.1 |
| 2023 | |||||||||||
| 4.3 | 3.5 | 2 | 3.8 | -8.2 | 2.9 | -7.2 | -1.7 | -8.9 | -12.7 | 11.5 | 22.5 |
| 2022 | |||||||||||
| -21.1 | -18.2 | 10.3 | -17.5 | -4.1 | 0.2 | 3.7 | 0.4 | -42.2 | 1.8 | 33.3 | -8.4 |
| 2021 | |||||||||||
| 87.1 | -20 | 5.7 | -6.9 | -19.3 | 11.5 | -13.5 | 16.6 | 5.3 | 4.8 | 11 | -2.5 |
| 2020 | |||||||||||
| -15.1 | 7.9 | -24.4 | 35.6 | 3 | 10.1 | 4.8 | -12.4 | -5.1 | -15.4 | 2.5 | 17.3 |
EPS
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Q1 | 2.3 | -0.9 | 1.1 | -1.5 |
| Q2 | 0.1 | -0.1 | 1.8 | 1.3 |
| Q3 | -0.6 | 0 | 0.8 | -0.4 |
| Q4 | 0 | -1 | -0.3 | 0.4 |
| A | 1.87 | -2 | 3.3 | -0.2 |